Teratogenic Risk Potentiality of Blue Ternate (Clitoria ternatea) Leaf Extract Using Chorioallantoic Membrane (CAM) Assay: Phase One

The study implemented a descriptive classic experimental design within a laboratory, utilizing the Chorioallantoic Membrane (CAM) assay to investigate the teratogenic potential of Blue Ternate (Clitoria ternatea) leaf extract using the different extract concentrations, and the phytochemical analysis screening unveiled the presence of flavonoids, saponins, tannins, alkaloids, and steroids in the leaves. The primary objectives encompassed the assessment of teratogenicity at various extract concentrations, comparing results with controls, and exploring the plant’s impact on embryonic development. While no significant differences emerged in primary and secondary blood vessels among treatments, a conspicuous variation in tertiary blood vessels indicated potential teratogenic effects at specific concentrations. Nevertheless, the study concluded that Clitoria ternatea exhibits promising therapeutic attributes. Recommendations include the implementation of public awareness programs elucidating the health benefits of Blue Ternate and further investigations into refining, storage practices, and potential teratogenicity in other plant parts. These insights, of considerable value to medical practitioners and future researchers, underscore the importance of caution and consultation, especially for pregnant individuals. In summary, the research significantly contributes to understanding Blue Ternate’s safety profile, presenting avenues for future exploration. The emphasis on careful consideration in medicinal applications, particularly during pregnancy, reinforces the need for responsible and informed decision-making in healthcare practices.